Experienced in Light Chain Deposition Disease (LCDD)

Dr. Jeffrey V. Matous

Hematology Oncology | Oncology | Hematology
Healthone Clinic Services - Oncology Hematology LLC
1721 E 19th Ave, Suite 300, 
Denver, CO 
Offers Telehealth
Experienced in Light Chain Deposition Disease (LCDD)
Healthone Clinic Services - Oncology Hematology LLC
1721 E 19th Ave, Suite 300, 
Denver, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Matous is a Hematologist Oncology specialist and an Oncologist in Denver, Colorado. Dr. Matous is rated as an Experienced provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Light Chain Deposition Disease (LCDD).

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CO
Hospital Affiliations
Hca Healthone Presbyterian St Lukes
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

HEALTHONE CLINIC SERVICES - ONCOLOGY HEMATOLOGY LLC
1721 E 19th Ave, Suite 300, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Enrollment Status: Terminated
Publish Date: May 09, 2023
Intervention Type: Drug, Other
Study Drugs: Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 1
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: M3258, Dexamethasone
Study Phase: Phase 1
View 9 Less Clinical Trials

53 Total Publications

Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia.
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia.
Journal: Seminars in hematology
Published: June 27, 2025
Similar Doctors
Experienced in Light Chain Deposition Disease (LCDD)
Dr. Sujatha Nallapareddy
Hematology Oncology | Hematology | Oncology
Experienced in Light Chain Deposition Disease (LCDD)
Dr. Sujatha Nallapareddy
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

10103 Ridgegate Pkwy, G01, 
Lone Tree, CO 
 (15.8 miles away)
303-925-0700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sujatha Nallapareddy is a Hematologist Oncology specialist and a Hematologist in Lone Tree, Colorado. Dr. Nallapareddy is rated as a Distinguished provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Iron Deficiency Anemia.

Experienced in Light Chain Deposition Disease (LCDD)
Dr. Mark A. Sitarik
Hematology Oncology | Hematology | Oncology
Experienced in Light Chain Deposition Disease (LCDD)
Dr. Mark A. Sitarik
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

4715 Arapahoe Ave, 
Boulder, CO 
 (23.4 miles away)
303-385-2000
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Sitarik is a Hematologist Oncology specialist and a Hematologist in Boulder, Colorado. Dr. Sitarik has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). His top areas of expertise are Heyde Syndrome, Von Willebrand Disease (VWD), Paget Disease of the Breast, and Breast Cancer.

Experienced in Light Chain Deposition Disease (LCDD)
Dr. Christopher B. Benton
Hematology Oncology | Oncology | Hematology
Experienced in Light Chain Deposition Disease (LCDD)
Dr. Christopher B. Benton
Hematology Oncology | Oncology | Hematology

Rocky Mountain Cancer Centers Llp

1700 S Potomac St, 
Aurora, CO 
 (8.4 miles away)
303-418-7600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Benton is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Benton is rated as a Distinguished provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matous's expertise for a condition
ConditionClose
View All 32 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile